Gefapixant

Last updated

Gefapixant
Gefapixant structure.svg
Clinical data
Trade names Lyfnua
Other namesMK-7264
ATC code
Legal status
Legal status
  • EU:Rx-only [1]
Identifiers
  • 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.258.106 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C14H19N5O4S
Molar mass 353.40 g·mol−1
3D model (JSmol)
  • CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC
  • InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)
  • Key:HLWURFKMDLAKOD-UHFFFAOYSA-N

Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. [1] It acts as an antagonist of the P2RX3 receptor. [2] [3] [4]

Contents

It was authorized for medical use in the European Union in September 2023. [1]

Medical uses

Gefapixant is indicated for the treatment of refractory or unexplained chronic cough. [1]

Society and culture

Names

It was named in honour of Geoff Burnstock. [5]

References

  1. 1 2 3 4 "Lyfnua EPAR". European Medicines Agency. 29 September 2023. Retrieved 5 October 2023.
  2. ↑ Muccino D, Green S (June 2019). "Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough". Pulmonary Pharmacology & Therapeutics. 56: 75–78. doi: 10.1016/j.pupt.2019.03.006 . PMID   30880151. S2CID   81982653.
  3. ↑ Richards D, Gever JR, Ford AP, Fountain SJ (July 2019). "Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation". British Journal of Pharmacology. 176 (13): 2279–2291. doi:10.1111/bph.14677. PMC   6555852 . PMID   30927255.
  4. ↑ Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, et al. (December 2019). "Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications". Expert Opinion on Therapeutic Patents. 29 (12): 943–963. doi:10.1080/13543776.2019.1693542. hdl: 11581/435751 . PMID   31726893. S2CID   208037373.
  5. ↑ Ford AP, Dillon MP, Kitt MM, Gever JR (November 2021). "The discovery and development of gefapixant". Autonomic Neuroscience. 235: 102859. doi:10.1016/j.autneu.2021.102859. PMID   34403981. S2CID   236524967.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.